A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor alpha (PDGFR alpha) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS) Meeting Abstract
| Authors: | Tap, W. D.; Jones, R. L.; Chmielowski, B.; Elias, A. D.; Adkins, D.; Van Tine, B. A.; Agulnik, M.; Cooney, M. M.; Livingston, M. B.; Pennock, G. K.; Qin, A.; Shahir, A.; Ilaria, R. L.; Conti, I.; Cosaert, J.; Schwartz, G. K. |
| Abstract Title: | A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor alpha (PDGFR alpha) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036900136 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.10501 |
| Notes: | Meeting Abstract: 10501 -- Source: Wos |
